Evidence map›Paper›PMID 41776123›Full record

ReviewCancer metastasis reviews2026

Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors.

Marlène Deschuyter, Sophie Martin, Chinar Salmanli, Clémence Hubsch, Audrey Vincent, Samuel Meignan, Alessandro Furlan, Erika Cosset, Hélène Burckel, Georges Noel and 14 more

Abstract readReview
In one paragraph

Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Marlène DeschuyterEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France. deschuyter@unistra.fr.
Sophie MartinEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Chinar SalmanliEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Clémence HubschEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Audrey VincentEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Samuel MeignanEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Alessandro FurlanEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Erika CossetGLIMMER Of lIght (GLIoblastoma MetabolisM, HetERogeneity, and OrganoIds), Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR 5286, Lyon, France.
Hélène BurckelEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Georges NoelEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Michel SalzetEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Marie DuhamelEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Antonella Raffo-RomeroEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Cedric BouraEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Sophie PinelEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Andres CocaNeurosurgery Department, University Hospitals of Strasbourg, Strasbourg, France.
Antony JoudNeurosurgery Department, University Hospital of Nancy, Vandoeuvre Les Nancy, France.
Mélodie Anne KarnoubNeurosurgery Department, University Hospital of Lille, Lille, France.
Pascal ChastagnerEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Sandra RaimbaultEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Hélène Sudour-BonnangeEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Vincent FlacherEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Chloé BernhardEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France.
Natacha Entz-WerléEN-HOPE SMART4CBT Research Center, PEDIACRIEX, Lille, Nancy, Strasbourg, University Hospitals of Strasbourg, Strasbourg, France. Natacha.entz-werle@chru-strasbourg.fr.

Funding

Institut National Du Cancer PEDIACRIEX
6 · The paper itself

Abstract

Pediatric malignant brain tumors (PMBTs) remain among the most common and challenging cancers in children and adolescents, with current therapies often failing to deliver satisfactory outcomes. A major obstacle is their intrinsic and extrinsic resistance mechanisms, underscoring the urgent need for innovative therapeutic strategies and accurate preclinical modeling. Recent advances in organoid-based technologies offer promising tools to mimic PMBTs more faithfully in vitro. These three-dimensional (3D) models can replicate key features of the tumor and its brain-like microenvironment, providing valuable platforms for studying resistant cancer cells and testing novel treatment approaches. This review discusses the relevance of cultured 3D systems, organoids and tumoroids, in pediatric neuro-oncology, emphasizing their role in precision medicine. These models have become essential for dissecting the complex biology and dynamic biological processes of all PMBTs, while bridging clinical challenges with experimental discoveries, ultimately enabling more effective and personalized treatments for young patients.

Indexed as

Brain NeoplasmsOrganoidsAnimalsChildHumansPrecision MedicineTumor Microenvironment3D cultureBrain tumorsCerebroidMicrofluidicOrganoidPediatricTumoroid

Identifiers

PMID41776123
PMCPMC12957049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.